Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Drops By 61.5%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 49,400 shares, a drop of 61.5% from the February 13th total of 128,400 shares. Approximately 176.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 260,900 shares, the short-interest ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, HC Wainwright decreased their target price on TC Biopharm from $112.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, December 6th.

TC Biopharm Stock Performance

TC Biopharm stock opened at $1.70 on Thursday. TC Biopharm has a fifty-two week low of $1.43 and a fifty-two week high of $523.20. The firm’s fifty day moving average price is $4.95 and its 200-day moving average price is $33.23.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.